It has recently been reported that intravenous ustekinumab, which is an anti-IL-12 antibody, induces response and remission in patients with moderately to severely active Crohn’s disease, an inflammatory bowel disease (IBD) that is refractory to TNF-α antagonists [53]. The gene discussed is TNF; the disease is inflammatory bowel disease.